

CASE REPORT

Open Access



Multidisciplinary approach and anesthetic management of a surgical cancer patient with methylene tetrahydrofolate reductase deficiency: a case report and review of the literature

Marco MC Cascella^{1*}, Manuela MA Arcamone², Emanuela EM Morelli², Daniela DV Viscardi⁴, Viera VR Russo⁴, Silvia SDF De Franciscis³, Andrea AB Belli³, Rosanna RA Accardo¹, Domenico DC Caliendo¹, Elena EDL De Luca¹, Barbara BDC Di Caprio¹, Francesco FDS Di Sauro¹, Giovanni GG Giannoni¹, Carmine CI Iermano¹, Maria MM Maciariello¹, Marcella MM Marracino¹ and Arturo AC Cuomo¹

Abstract

Introduction: Hyperhomocysteinemia is a known risk factor for myocardial infarction, stroke, peripheral vascular disease, and thrombosis. Elevated plasma homocysteine levels have been demonstrated in patients with recurrent episodes or a single episode of thrombosis. Here we describe the development of cardiovascular disease as a complication of a surgical intervention in a patient with colorectal cancer and hyperhomocysteinemia.

Case presentation: A 65-year-old Caucasian man complained of pain and constipation, attributed to previously diagnosed adenocarcinoma (stage IIB) of the hepatic flexure. An anamnestic investigation showed that he had undergone two surgical interventions. During both, he suffered thrombotic postoperative complications, a deep vein thrombosis of the upper extremity after the first operation and retinal vein occlusion after the second. He was diagnosed with hyperhomocysteinemia associated with a homozygous C677T mutation of the gene encoding the enzyme methylenetetrahydrofolate reductase. Our patient was initially treated with folic acid and high-dose B vitamins. On day 7 he underwent a right hemicolectomy. Anesthesia was performed with sevoflurane in 40% O₂ and without the use of nitrous oxide. Postoperatively, our patient remained on folic acid and B vitamins and was without immediate or subsequent complications.

Conclusions: Neoplastic disease and related surgery followed by the administration of chemotherapeutic drugs alter the hemostatic balance in cancer patients. Those suspected of also having a thrombophilic disease require a thorough laboratory diagnostic workup, including a molecular analysis aimed at identifying the genetic mutation responsible for the hyperhomocysteinemia, as indicated. The case described in this report highlights the importance of a multidisciplinary approach that includes expertise in peri-operative anesthesia, surgery, oncology, and hematology.

* Correspondence: m.cascella@istitutotumori.na.it

¹Division of Anesthesia, Department of Anesthesia, Endoscopy and Cardiology, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCSS, Naples, Italy

Full list of author information is available at the end of the article

Introduction

Clinical and epidemiological studies have shown that alterations in homocysteine (Hcy) metabolism play a role in atherosclerosis [1–3]. This would explain the approximately 20% of patients with atherosclerotic vascular disease but without any known cardiovascular risk factors, such as a family history, diabetes, smoking, and high blood pressure [4].

Hcy is a sulfur-containing amino acid that is formed during the methionine (MET) cycle. MET is an essential amino acid present in proteins of animal origin. Dietary MET is converted from adenosyltransferase methionine to S-adenosylmethionine (SAM). As the major donor of the methyl groups required in transmethylation reactions, SAM is critical to the synthesis of proteins, nucleic acids, creatinine, phospholipids, and neurotransmitters. The plasma level of Hcy is controlled by two distinct metabolic pathways. In the first, Hcy is degraded to cysteine, which is eliminated via the kidney; in the second, Hcy is converted to MET through a methylation reaction in which Hcy acquires a methyl group from either N5-methyltetrahydrofolate (MTHF) or from betaine and is then reconverted to MET. MET methylation is catalyzed by MET synthase using vitamin B12 as a cofactor and MTHF as the methyl donor. MTHF is formed from folic acid by the enzyme N5, N10 methylenetetrahydrofolate reductase (MTHFR). This MET recovery pathway contributes to regulating the serum Hcy concentration, and alterations therein underlie the development of Hcy-related atherosclerosis [5].

Under normal conditions, there is a close balance between the formation and elimination of Hcy, with approximately 50% being methylated to MET. In the presence of excess MET, a larger amount is converted to cysteine via a transsulfuration reaction. If the rate of cellular Hcy formation is faster than the rate of Hcy consumption, the excess is released into the circulation, leading to hyperhomocysteinemia (HHcy).

A possible cause of HHcy is the presence of genetic abnormalities that affect both the sulfuration reaction and the methylation of Hcy to MET. Two known MTHFR polymorphisms are associated with the reduced activity of the enzyme and therefore with increased levels of Hcy: the C677T polymorphism and the A1298C polymorphism. Of these, the former is considered the most important genetic determinant of Hcy concentrations.

MTHFR mutations are relatively common. For example, homozygosity for MTHFR C677T is present in 0–3% of African Americans and in 9–11% of Caucasian Americans. These mutations may remain undetected but they are also associated with an increased incidence of thrombotic diseases. However, in rare cases defects in MTHFR cause severe increases in plasma Hcy, leading to gait abnormalities, seizures, and psychiatric manifestations. Here we describe

the development of cardiovascular disease as a complication of a surgical intervention in a patient with colorectal cancer and hyperhomocysteinemia.

Case presentation

A 65-year-old Caucasian man complained of pain and constipation related to adenocarcinoma (stage IIB) involving the hepatic flexure. He had a long-standing history of hypertension, but it was well controlled with a beta blocker. An anamnestic investigation showed that he had been operated on twice: approximately 10 years earlier he had undergone surgical repair of an inguinal hernia, and 2 months earlier, a transurethral resection for a papillomatous lesion of the bladder. Following both surgeries, he had symptoms indicative of thrombotic complications. The first operation was followed by the rapid onset of postoperative pain in the left arm, with swelling and redness. These symptoms lasted for approximately 1 month and were treated with antibiotics and low-molecular-weight heparin. His symptoms suggested a deep vein thrombosis (DVT) of the upper extremity, a suspicion confirmed by the finding of prominent veins in our patient's left arm. After the second intervention, he experienced a severe loss of vision in his left eye, attributed to retinal vein branch occlusion (RVO).

Our patient's prior history was consistent with a hemostatic disorder. Before undergoing surgery for his cancer-related complaints, a complete screening for risk factors of thrombosis was performed. The levels of C and S proteins were in the normal range; his serum Hcy level was 25 $\mu\text{mol/L}$. A subsequent molecular analysis showed homozygosity for the MTHFR C677T mutation. He did not have the Leiden variant of factor V. Treatment with folic acid (25mg/day intramuscularly (i.m.)), cocarboxylase (38mg/day, i.m.), pyridoxine hydrochloride (300mg/day, i.m.), hydroxocobalamin (5000 $\mu\text{g/day}$, i.m.), and antiplatelet therapy with low-dose aspirin was started. After his serum Hcy level had decreased to 18 $\mu\text{mol/L}$, he underwent a right hemicolectomy. Low-dose aspirin therapy was maintained. Anesthesia was performed with sevoflurane in 40% O₂, without the use of nitrous oxide (N₂O).

The operative course was uneventful and there were no immediate or late complications as determined in a physical examination, molecular laboratory analysis, blood test, and Doppler ultrasound screening of the upper and lower extremities performed 7 days, 15 days, 1 month, 3 months, and 6 months postoperatively. His serum Hcy levels were 13 $\mu\text{mol/L}$, 11.5 $\mu\text{mol/L}$, 10.4 $\mu\text{mol/L}$, 9.8 $\mu\text{mol/L}$, and 8.7 $\mu\text{mol/L}$, respectively.

Antithrombotic therapy after surgery consisted of 100mg of intravenous acetylsalicylic acid every 24 hours starting 12 hours after the end of the surgery. On day 3, our patient resumed oral therapy with low-dose aspirin. The administration of B vitamins continued with high

doses during the first 7 postoperative days, followed by oral folic acid (15mg/day) and hydroxocobalamin (5µg/day) for maintenance.

Discussion

The suspicion that our patient had a genetically determined hemostatic alteration arose when his anamnesis included thrombotic complications after previous surgeries.

DVT of the upper extremity is a rare event, accounting for only 1-4% of DVTs [6]. This complication is usually associated with the placement of a central venous catheter [7]; however, this was not the case in our patient, in whom the device was never implanted. His report of RVO led us to investigate the clinical aspects and pathogenesis underlying his medical history. HHcy was recently identified as an emerging risk factor for RVO. Although the main risk factors are hypertension and glaucoma, elevated serum Hcy levels are a more frequent occurrence than other known risk factors for cardiovascular diseases (for example, diabetes, dyslipidemia, smoking, hyperviscosity syndrome, and vasculitis) in patients with RVO. This association is supported by the high frequency of homozygosity for the C677T MTHFR gene polymorphism in patients with RVO [8, 9].

Once the diagnosis of thrombophilic disease was established, an appropriate peri-operative protocol was chosen. Surgery and its related stress can alter the patient's hemostatic balance; this is especially the case in cancer patients. Indeed, the increased risk of thromboembolism in cancer patients has long been recognized, and it has been attributed to the complex state of hypercoagulability. Chemotherapy enhances the risk of thrombosis by causing endothelial damage.

Cancer-related thrombosis is the second leading cause of death (after cancer itself) in cancer patients and is accompanied by a marked worsening of the prognosis [10]. Therefore, in this cohort of patients, it is of fundamental importance to promptly identify additional factors leading to an increased thrombophilic risk, as this will insure a timely intervention aimed at minimizing thrombotic complications during the postoperative period.

Peri-operative changes in hemostasis have a multifactorial origin but may also be secondary to medications, including anesthetic agents. In fact, most anesthetics, including those administered intravenously, volatile anesthetics, and local anesthetics, have been linked to the inhibition of platelet function, albeit to varying extents [11, 12].

The anesthetic agent with the greatest impact on folate metabolism is N₂O, which deactivates cobalamin via an oxidation reaction and causes an irreversible block of MET synthase, located at the confluence of Hcy methylation and the folate cycle. This results in a sustained increase in plasma Hcy concentrations and in the absence of biologically active folate ('folate trapping') that can be

used for the conversion of Hcy to MET [13]. Therefore, N₂O-induced MET synthase inhibition in patients with MTHFR mutations can cause severe hematological and neurological effects and the use of N₂O during anesthesia should therefore be avoided in this cohort.

Over the last 30 years, more than a dozen clinical cases have been published in which N₂O anesthesia led to neurological complications, including myelopathy, peripheral neuropathy, and hemiparesis, caused by a lack of MET in the brain [14, 15].

The neurological damage caused by N₂O is often accompanied by hematological abnormalities, such as megaloblastic anemia and bone marrow disorders. Selzer *et al.* [16] proposed the 'double-hit' mechanism to explain the neurological deterioration and death of a child anesthetized twice with N₂O. This hypothesis links HHcy and the N₂O-induced inhibition of folate metabolism with a defect in the MTHFR gene. Our case study suggests that the 'double-hit' hypothesis is also applicable to patients with a cobalamin or folate deficiency who are exposed to N₂O, for example, patients with other MTHFR gene polymorphisms [17]. Thus, in patients in whom altered Hcy metabolism is suspected, a more in-depth molecular diagnosis and, if the surgical intervention cannot be postponed, the avoidance of N₂O-containing anesthesia are recommended.

Badner *et al.* described an association between Hcy and a significant increase in the incidence and duration of postoperative ischemia in patients receiving N₂O-containing anesthesia for carotid endarterectomy [18].

Although the inhibition of cobalamin and HHcy after N₂O administration is transient, lasting only for a few days [19], the effect coincides with the postoperative period, during which the patient is particularly vulnerable, as evidenced by the very high risk of serious cardiovascular complications on postoperative days 2 and 3 [20, 21]. In addition, Hcy levels seem to correlate with the duration of N₂O exposure. The preoperative administration of B vitamins can prevent the effects induced by N₂O [22].

In the ENIGMA study, patients undergoing noncardiac surgery who were at low cardiovascular risk and exposed to N₂O had an unexpectedly high number of myocardial infarctions [23]. Recent studies have also shown that patients homozygous for the MTHFR mutation who receive N₂O anesthesia have higher postoperative plasma Hcy levels than patients who are heterozygous for the mutation or carry the wild-type gene [24].

In contrast to previous work, Nagele *et al.* [25] suggested that neither N₂O-induced HHcy nor MTHFR gene polymorphisms are associated with postoperative cardiac events. This implies a minor role for genetic influences in the response to anesthesia and that the prophylactic use of B vitamins would thus be effective in

reducing anesthesia-induced increases in Hcy levels but not peri-operative cardiac events.

To determine the true impact of N₂O on cardiovascular events requires a large and rigorous study. The results of ENIGMA II, in which 7000 patients undergoing major surgery were enrolled, supports the safety profile of N₂O for use in major noncardiac surgery, although these patients had normal Hcy values [26].

Another consideration related to the MTHFR mutation is its association with colorectal cancer and its interference with chemotherapy. MTHFR plays an important role in folate metabolism, which has been implicated in carcinogenesis because of the folate dependence of methylation, repair, and DNA synthesis. In previous work, we analyzed the relationship between C677T and A1298C MTHFR gene polymorphisms and the biological, pathological, genetic, and epigenetic characteristics of several different tumor types and their response to chemotherapy with 5-fluorouracil. The aim of that study was to determine the contribution of the MTHFR genotype to the susceptibility to colorectal cancer and the response to treatment [27–29]. While some authors have reported the protective effect of the allelic variant C677T in the development of several cancers [27, 28], the meta-analysis of Pu *et al.* showed an association between this polymorphism and an increased susceptibility to ovarian cancer in the Asian population [29]. In addition, the MTHFR A1298C polymorphism is reportedly associated with a high risk of colon cancer [30], but according to the meta-analysis of Zhao *et al.* [31] both the MTHFR 677T and the 1298C alleles are associated with a low risk of colorectal cancer. This finding further emphasizes the uniqueness of our case because we found the C677T mutation in our patient. Both polymorphisms may also be influenced by independent factors that in turn determine the response to 5-fluorouracil. Thus, MTHFR genotyping may guide the selection of the optimal treatment regimen [32].

Conclusions

Patients with neoplastic disease frequently undergo surgery, followed by the administration of chemotherapy. Because these three factors are known to alter hemostatic balance, the suspicion of a thrombophilic disease in a cancer patient must include a thorough laboratory diagnostic evaluation. If elevated serum Hcy levels are found, a complete screening, including a molecular analysis aimed at identifying the type of genetic mutation, is warranted.

Our case study also emphasizes the importance of a multidisciplinary approach. Multicenter studies have sought to quantify the cardiovascular complications associated with the use of N₂O in patients with HHcy. The ENIGMA II study showed that N₂O does not increase the risk of death and cardiovascular complications or

surgical site infection in patients undergoing major non-cardiac surgery. However, these results are valid only for patients with normal Hcy values. Whether MTHFR gene polymorphisms are associated with an increased risk of N₂O-induced cardiac events remains to be determined. In the meantime, however, the use of N₂O in these patients should be avoided and the thrombophilic effect of HHcy minimized using acetylsalicylic acid prophylaxis, folic acid, and B vitamins. Finally, our results have oncological implications, as they suggest that MTHFR polymorphisms influence the susceptibility to colorectal cancer.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MC, MA and EM have made substantial contributions to conception and design of the study. DC, DV, VR, SDF and AB have been involved in drafting the manuscript. RA, EDL, BDC, FDS, CI, MM, MM, AC and GG have given final approval of the version to be published.

Author details

¹Division of Anesthesia, Department of Anesthesia, Endoscopy and Cardiology, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy. ²Division of Haematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy.

³Department of Abdominal Oncology Surgery, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy. ⁴Department of Surgery, Anesthesia, Emergency and Intensive Care, University of Naples "Federico II", Naples, Italy.

Received: 28 November 2014 Accepted: 27 July 2015

Published online: 20 August 2015

References

- Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ*. 2002;325:1202.
- Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. *J Inher Metab Dis*. 2011;34:75–81.
- Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. *Lancet*. 1999;354:407–13.
- Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, *et al.* Prevalence of conventional risk factors in patients with coronary heart disease. *JAMA*. 2003;290:898–904.
- Finkelstein JD, Martin JJ, Harris BJ. Methionine metabolism in mammals. The methionine-sparing effect of cysteine. *J Biol Chem*. 1988;263:11750–4.
- Malhotra S, Punia VP. Upper extremity deep vein thrombosis. *J Assoc Phys India*. 2004;52:237–41.
- Martin C, Viviani X, Saux P, Gouin F. Upper-extremity deep vein thrombosis after central venous catheterization via the axillary vein. *Crit Care Med*. 1999;27:2626–9.
- Prisco D, Bertini L, Marcucci R, Poli D. [Retinal vein occlusions: diseases for the internist?]. *Ann Ital Med Int*. 2000;15:75–84.
- Ferrazzi P, Di Micco P, Quaglia I, Rossi LS, Bellatorre AG, Gaspari G, *et al.* Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion. *Thromb J*. 2005;3:13.
- Khorana AA. Venous thromboembolism and prognosis in cancer. *Thromb Res*. 2010;125:490–3.

11. Faraday N. Platelets, perioperative hemostasis, and anesthesia. *Anesthesiology*. 2002;96:1042–3.
12. Kozek-Langenecker SA. The effects of drugs used in anaesthesia on platelet membrane receptors and on platelet function. *Curr Drug Targets*. 2002;3:247–58.
13. Deacon R, Lumb M, Perry J, Chanarin I, Minty B, Halsey MJ, et al. Selective inactivation of vitamin B12 in rats by nitrous oxide. *Lancet*. 1978;2:1023.
14. Felmet K, Robins B, Tilford D, Hayflick SJ. Acute neurologic decompensation in an infant with cobalamin deficiency exposed to nitrous oxide. *J Pediatr*. 2000;137:427–8.
15. Hadzic A, Glab K, Sanborn KV, Thys DM. Severe neurologic deficit after nitrous oxide anesthesia. *Anesthesiology*. 1995;83:863–6.
16. Selzer RR, Rosenblatt DS, Laxova R, Hogan K. Adverse effect of nitrous oxide in a child with 5,10-methylene tetrahydrofolate reductase deficiency. *N Engl J Med*. 2003;349:45–50.
17. Nagele P, Zeugswetter B, Wiener C, Burger H, Hupfl M, Mittlbo M, et al. Influence of methylene tetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. *Anesthesiology*. 2008;109:36–43.
18. Badner NH, Beattie WS, Freeman D, Spence JD. Nitrous oxide- induced increased homocysteine concentrations are associated with increased postoperative myocardial ischemia in patients undergoing carotid endarterectomy. *Anesth Analg*. 2000;91:1073–9.
19. Koblin DD, Tomerson BW. Methionine synthase activities in mice following acute exposures to ethanol and nitrous oxide. *Biochem Pharmacol*. 1989;38:1353–8.
20. Fleischmann KE, Goldman L, Young B, Lee TH. Association between cardiac and non cardiac complications in patients undergoing non cardiac surgery: Outcomes and effects on length of stay. *Am J Med*. 2003;115:515–20.
21. Badner NH, Knill RL, Brown JE, Novick TV, Gelb AW. Myocardial infarction after non cardiac surgery. *Anesthesiology*. 1998;88:572–8.
22. Badner NH, Drader K, Freeman D, Spence JD. The use of intraoperative nitrous oxide leads to postoperative increases in plasma homocysteine. *Anesth Analg*. 1998;87:71.
23. Myles PS, Leslie K, Chan MTV, Forbes A, Paech MJ, Peyton P, et al. Avoidance of nitrous oxide for patients undergoing major surgery. *Anesthesiology*. 2007;107:221–31.
24. Nagele P, Zeugswetter B, Hupfl M, Mittelboeck M, Foedinger M. Influence of mutations in the MTHFR gene on homocysteine levels after nitrous oxide anesthesia [abstract]. *Anesthesiology*. 2007;107:A7.
25. Nagele P, Brown F, Francis A, Scott MG, Gage BF, Miller JP, et al. Influence of nitrous oxide anesthesia, B-vitamins, and MTHFR gene polymorphisms on perioperative cardiac events: the vitamins in nitrous oxide (VINO) randomized trial. *Anesthesiology*. 2013;119:19–28.
26. Myles PS, Leslie K, Chan MT, Forbes A, Peyton PJ, Paech MJ, et al. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. *Lancet*. 2014;384:1446–54.
27. Guo S, Jiang X, Chen X, Chen L, Li X, Jia Y. The protective effect of methylene tetrahydrofolate reductase C677T polymorphism against prostate cancer risk: evidence from 23 case-control studies. *Gene*. 2015;565:90–5. doi:10.1016/j.gene.2015.03.067.
28. Zhuo WL, Zhang L, Ling JJ, Zhu Y, Chen ZT. MTHFR C677T and A1298C polymorphisms and cervical carcinoma susceptibility: meta-analyses based on 4,421 individuals. *Mol Biol Rep*. 2012;39:8723–32.
29. Pu D, Jiang SW, Wu J. Association between MTHFR gene polymorphism and the risk of ovarian cancer: a meta-analysis of the literature. *Curr Pharm Des*. 2014;20:1632–8.
30. Rai PS, Pai GC, Alvares JF, Bellampalli R, Gopinath PM, Satyamoorthy K. Intra-individual somatic variations in MTHFR gene polymorphisms in relation to colon cancer. *Pharmacogenomics*. 2014;15:349–59.
31. Zhao M, Li X, Xing C, Zhou B. Association of methylene tetrahydrofolate reductase C677T and A1298C polymorphisms with colorectal cancer risk: a meta-analysis. *Biomed Rep*. 2013;5:781–91.
32. Fernández-Peralta AM, Dáimiel L, Nejda N, Iglesias D, Arana VM, González Aguilera JJ. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. *Int Colorectal Dis*. 2010;25:141–51.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

